Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121771 | 0.92 | CYP2A6 (0.37) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL17842734 | 0.82 | CYP2A6 (0.42) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL31015952 | 0.82 | CYP2A6 (0.42) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL826944 | 0.82 | CYP2A6 (0.42) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL17970824 | 0.78 | CYP2A6 (0.39) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL10045628 | 0.78 | CYP2A6 (0.39) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL25091874 | 0.75 | KDM4E (0.43) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL21931029 | 0.75 | DYRK1A (0.42) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL13736464 | 0.75 | CYP2A6 (0.37) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL30714299 | 0.75 | CYP2A6 (0.37) | CYP2A6DYRK1APTPRCPTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| US-20200165519-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20190276744-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-12 | — | — | US | disclosed |
| US-10407619-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10336938-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170283700-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| EP-0790246-B1 | POTENTIATOR FOR NERVE GROWTH FACTOR ACTIVITY CONTAINING 1,2-ETHANEDIOL DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-6103754-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-1020427-A1 | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6034119-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| US-5968935-A | ADMINISTERING TO TREAT NERVOUS SYSTEM DISORDERS | TOYAMA CHEMICAL CO.., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5932620-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5922721-A | USE IN TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S CHOREA, AMYOTROPHIC LATERAL SCLEROSIS AND TRAUAMTIC NERVE INJURIES | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5807887-A | COGNITION ACTIVATOR; ALZHEIMER*S, HUNTINGTON DISEASE | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0790246-A1 | POTENTIATOR FOR NERVE GROWTH FACTOR ACTIVITY CONTAINING 1,2-ETHANEDIOL DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | CYP2A6 3817/4885DYRK1A 1215/4885PTPRC 3035/4885 |
| US-10407619-B2 | Liquid crystal composition | RCC1, CCDC47, ACIN1 | CYP2A6 3817/4885DYRK1A 1215/4885PTPRC 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.